Cancer vaccine based on Brother of Regulator of Imprinted Sites Molecule
(No. in US: US000007579452B2. Date: 08/25/2009. Regions issued in: Australia, Canada, Europe, Сhina, Russia)
Polynucleotides encoding a nonfunctional mutant form of the Brother of Regulator of Imprinted Sites (BORIS) molecule, nonfunctional mutated BORIS protein, polypeptide or peptide and modified protein forms of BORIS are described. These molecules are used as a therapeutic vaccine against cancer.
Epitope vaccine for prevention and reversion of AD pathology
(No. in US: WO002009029272A3. Date: 12/23/2009.)
Vaccines for treating Alzheimer’s disease (AD) comprising specific epitopes, including a self B cell epitope of amyloid peptide, a foreign T cell epitope derived from conventional vaccines or pathogens and a molecular adjuvant are disclosed. The approach uses a plurality of copies of the B cell epitope in vaccine composition to significantly enhance the anti-amyloid beta humoral responce. Inclusion of various Th epitopes in the composition allows quick and potent induction od potent anti-amyloid beta antibody responses using pre-existing memory CD4+ Th cells induced in a general population by previous infections or immunizations with conventionalvaccines.
Proteins for use in diagnosing and treating infection and disease
(No. in US: US020090291884A1. Date: 08/07/2008. Regions issued in: Australia, Canada, Europe)
The present invention describes a composition comprised on cystatin A and at least one hystone used in diagnostic and treatment of dieases associated with reduced T helper cell counts such as HIV-1 infection, AIDS, ARC, multiple sclerosis, chronic fatigue syndrome, heumatoid arthritis, Alzheimer’s disease, dermatitis, type 1 diabetes mellitus, colitis, inflammatory bowel disease / irritable bowel syndrome, Chrhn’s disease, Psoriasis, Chronic obstructive pulmonary disease, system lupus erythematosus, transplant rejection and cancer.
Vaccines and gene therapy compositions and methods of making and using the same
(No. in US: US020030176378A1. Date: 09/18/2003. Regions issued in: Australia, Brazil, Canada, China, Europe, Korea, Japan, Mexico)
Methods of inducing an immune response against an immunogen in an individual are disclosed. The methods comprise administering to the individual, one or more nucleic acid molecules that comprise a nucleotide sequence that encodes an immunogen and a nucleotide sequence that encodes an Major Histocompatibility Complex antigen. The nucleotide sequences that encode the immunogen and the Major Histocompatibility Complex antigen are expressed when taken up by cells of the individual and an immune response against the immunogen is induced in the individual. Methods of reducing rejection of unmatched donor cells, tissue or organ in an individual undergoing cell, tissue or organ transplantation are disclosed. The methods comprise administering to the individual, one or more nucleic acid molecules that comprise a nucleotide sequence that encodes a death signal or toxin and a nucleotide sequence that encodes a Major Histocompatibility Complex antigen that is matched to the donor cells, tissue or organ. The nucleotide sequences that encode the Major Histocompatibility Complex antigen and death signal or toxin are expressed when taken up by cells of the individual. T cell death through interaction with the death signal or toxin results in a reduction of rejection of unmatched donor cells, tissue or organ. Methods of reducing a dominant immune response in an individual and methods of expanding a subpopulation of T cells associated with a specific immune response are also described. Plasmids and compositions comprising plasmids useful for practicing the method are described.
Nucleic acids encoding mutant human CD80 and compositions comprising the same
(No. in US: US000007446189B1. Date: 11/04/2008. Regions issued in: Australia, Brazil, Canada, China, Europe, Korea, Mexico)
Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.
Clip inhibitors and methods of modulating immune function
(No. in US: WO002010011347A2. Date: 01/28/2010.)
The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, allergic disease transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS.
Methods of RNA and protein synthesis
(No. in US: US000007186525B2. Date: 02/10/2005. Regions issued in: Austria, Australia, Europe)
The present invention relates to improved methods for RNA and/or protein synthesis using in vitro or in vivo expression systems. More specifically, the present invention provides a method for RNA and/or protein synthesis in cellular or cell-freeexpression systems characterized in that the concentration of α subunit of RNA polymerase, but not other subunits thereof, is increased in said cellular or cell-free system, comparing to its natural concentration existing in said cellular or cell-free system.
Methods for detecting of intermolecular interactions using protein arrays
(No. in Europe: WO002003012451A3. Date: 12/11/2003. Regions issued in: Austria, Australia, Germany, Europe)
The present invention relates to a method for the detection of intermolecular interactions between probe(s) and protein targets, said targets including at least one protein or polypeptide, which, when expressed in vivo into host cells, is toxic for said host cells or cannot be purified, or does not fold correctly. In particular, the invention results from the combination of the preparation of protein arrays with cell-free synthesized proteins and the detection of specific interactions using infra-red fluorescent dyes. The invention also relates to protein arrays and methods for their preparation. A cell-free method for protein synthesis involves the addition of purified alpha subunit of RNA polymerase. An array of crude cells extracts (with non-purified proteins) is good enough for the detection of DNA-protein and protein-protein interactions.